Skip to contentpdufa.bio

ZANVASTRO (zilganersen): FDA NDA 220210

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 220210 is the FDA application for ZANVASTRO (zilganersen). The FDA's Orange Book lists the applicant of record as IONIS PHARMACEUTICALS INC and the first approval on it as Sep 3, 2026. Code name used in development: ION373. Owner today: Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220210 · Orange Book NDA 220210

Names for this drug

Brand name (FDA)ZANVASTRO
Orange Book trade name: ZANVASTRO
Active ingredient (FDA)ZILGANERSEN SODIUM
Code nameION373
Source: Ionis Pharmaceuticals press release, Oct 1, 2024
“About Zilganersen (ION373)”

Who holds the application

FDA applicant of recordIONIS PHARMACEUTICALS INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayIonis Pharmaceuticals, Inc. (IONS)
Source: Ionis Pharmaceuticals press release, Sep 3, 2026
“Ionis Pharmaceuticals, Inc. (Nasdaq: IONS)”
Earlier / partnerRecordati: partner on the drug
Source: Ionis Pharmaceuticals press release, Sep 3, 2026
“Recordati obtained exclusive rights to develop and commercialize zilganersen in all countries outside the U.S.”

Products on NDA 220210 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001ZANVASTROSOLUTION;INTRATHECALEQ 56MG BASE/2.8ML (EQ 20MG BASE/ML)Sep 3, 2026

FDA decisions we track for this drug

Zilganersen (ION373)IONS · Decided

Drug page: /drug/zilganersen

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.